Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Combination co-stimulatory modulation: Moving from mouse to man Curran MA, Callahan, M., Allison JP, and Wolchok J MDACC Melaoma Seminar Series March, 2013
2. Systemic 4-1BB activation induces a novel T-cell phenotype driven by high expression of Eomesodermin Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP MDACC Center for Cancer Immunology Research Retreat December, 2012
3. Combination hypoxia-specific chemotherapy and immunotherapy cures established murine prostate cancer Curran MA, Subhudhi, S., Allison JP Cancer Research Institute Annual Meeting October, 2012
4. Systemic 4-1BB activation induces a novel T-cell phenotype driven by high expression of Eomesodermin Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP American Association of Immunologists Annual Meeting May, 2012
5. 4-1BB agonist antibody treatment induces production of IL-15 and IL-27 by antigen presenting cells driving the formation of a novel Eomes-dependent lineage of cytotoxic CD4+ and CD8+ T-cells Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP. Society for Immunotherapy of Cancer Annual Meeting October, 2011
6. 4-1BB agonist antibody treatment induces production of IL-15 and IL-27 by antigen presenting cells driving the formation of a novel Eomes-dependent lineage of cytotoxic CD4+ and CD8+ T-cells Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP Cancer Research Institute Annual Meeting October, 2011
7. 4-1BB agonist antibody treatment causes intra-tumoral accumulation of KLRG1+ CD8+ and CD4+ T-cells with a novel highly cytotoxic phenotype driven by the master-regulator Eomesodermin Curran MA, Kim MJ, Montalvo, WM, Al-Shamkhani A, Allison JP American Association of Immunologists Annual Meeting May, 2011
8. 4-1BB activation induces the master-regulator Eomes and a broad-spectrum TH1 phenotype which synergizes with CTLA-4 blockade to reject B16 melanoma Curran MA, Kim MJ, Al-Shamkhani A, Allison JP Cancer Research Institute Annual Meeting October, 2010
9. 4-1BB activation induces the master-regulator Eomes and broad-spectrum TH1 phenotype which synergizes with CTLA-4 blockade to reject B16 melanoma Curran MA, Kim MJ, Al-Shamkhani A, Allison JP International Society for Biological Therapy of Cancer Annual Meeting October, 2010
10. PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Curran MA, Montalvo W, Yagita H, Allison JP Keystone Symposia February, 2010
11. Cellular tumor vaccines expressing Flt3-ligand (FL3vax) synergize with a broad spectrum of immuno-adjuvant antibodies to drive the rejection of established tumors Curran MA, Allison JP Mobilizing Cellular Immunity for Cancer Therapy January, 2009
12. Cellular tumor vaccines expressing Flt3-ligand synergize with CTLA-4 blockade to reject established tumors Curran MA, Allison JP AACR Annual Meeting April, 2008
13. Adjuvants and alternatives for autologous tumor vaccination Curran MA, Allison JP American Association of Immunologists Annual Meeting May, 2006



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Building on the Success of CTLA-4 Blockade Through Biomarker Analyses and Development of Novel Combinatorial Strategies Chairperson: Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, New York, NY AACR Annual Meetings April, 2013

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.